Serum Institute of India starts manufacturing Codagenix's nasal COVID-19 vaccine2 min read . Updated: 22 Sep 2020, 09:11 PM IST
- The pre-clinical study of Codagenix's COVID-19 vaccine has showed promising results, the vaccine maker claimed
- Codagenix's COVID-19 vaccine is delivered intranasally rather than via an injection, Robert Coleman, Ph.D., CEO of Codagenix said
Serum Institute of India has started manufacturing COVID-19 vaccine candidate developed by Codagenix Inc, the US biotech firm said in a statement. Dubbed as CDX-005, the coronavirus vaccine candidate has completed pre-clinical animal studies. The company aims to initiate phase I clinical trial of its COVID-19 vaccine in the United Kingdom by the end of this year.
Select your Category